Krystal Biotech: recent performance snapshot

Krystal Biotech (KRYS) has drawn attention after a period of mixed share price moves, with a 1.4% gain over the past day, a 2.4% decline over the past week, and a 4.7% decline over the past 3 months.

At a share price of $266.04, Krystal Biotech’s recent 1 month share price return of 2.0% and 7.8% year to date share price return sit alongside a 1 year total shareholder return of 60.1%. This suggests that longer term momentum has been firmer than in the most recent few months.

If you are comparing Krystal Biotech with other opportunities in high growth healthcare, this could be a good moment to scan for promising healthcare AI names using the 33 healthcare AI stocks.

With a 60.1% 1 year total return and shares trading at a 60.2% discount to one intrinsic value estimate, the key question now is whether Krystal Biotech is still mispriced or if markets already reflect its valuation.

Most Popular Narrative: 15.5% Undervalued

Krystal Biotech’s most followed valuation narrative points to a fair value of $315 per share versus the last close of $266.04. This puts the focus squarely on how future execution lines up with that gap.

The expansion of Krystal's pipeline, including imminent and near-term clinical readouts in lung disease (AATD, CF), ophthalmology, oncology (NSCLC), and aesthetics, leverages increased R&D productivity, which could drive future revenue growth and diversify earnings beyond a single product. Favorable dynamics in global healthcare, such as greater willingness to reimburse curative, high-value genetic therapies and broadening awareness due to successful launches and patient outcomes, should support sustainable long-term revenue growth and premium pricing, boosting revenue visibility and potentially net margins.

Curious what kind of revenue ramp, margin lift, and future earnings multiple sit behind that $315 figure? The narrative leans on ambitious growth, richer profitability, and a valuation hurdle that still assumes a premium to the broader biotech group.

Result: Fair Value of $315 (UNDERVALUED)

However, this hinges on VYJUVEK staying on track and international reimbursement landing as expected, while rising R&D and SG&A could pressure profitability if revenue timing slips.

Another view on valuation

While the narrative points to a $315 fair value, the current P/E of 38.2x tells a different story. That is much higher than the US Biotechs industry at 16.3x, the peer average at 23.7x, and a fair ratio of 21.5x, which suggests meaningful valuation risk if expectations cool.

To see how this ratio based view compares with a more detailed cash flow framework, take a closer look at our valuation breakdown using the See what the numbers say about this price — find out in our valuation breakdown..

Next Steps

With sentiment this mixed, it makes sense to look past the headlines, review the underlying data, and move quickly to shape your own view by checking the 3 key rewards.

Looking for more investment ideas?

If Krystal Biotech has sparked your interest, do not stop here. The wider market holds plenty of other compelling setups worth lining up on your watchlist.

• Spot potential value opportunities early by reviewing companies highlighted in the screener containing 25 high quality undiscovered gems.
• Strengthen your core holdings with businesses featured in the solid balance sheet and fundamentals stocks screener (44 results).
• Add a defensive income angle by checking companies in the 13 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.